BioAge Labs (NASDAQ:BIOA) Given Sell (E+) Rating at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (e+)" rating on BioAge Labs (NASDAQ:BIOA), aligning with a recent downgrade from Wall Street Zen from "hold" to "sell." This reflects a consensus that the stock is underperforming.
• BioAge Labs has reported a quarterly earnings miss, with an EPS of ($0.60) compared to the expected ($0.56), indicating ongoing financial challenges.
• The stock's trading performance shows volatility, with a 52-week range from $2.88 to $26.62, and a current price of $5.67, highlighting significant fluctuation in investor confidence.

BioAge Labs (NASDAQ:BIOA - Get Free Report)'s stock had its "sell (e+)" rating reiterated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen lowered BioAge Labs from a "hold" rating to a "sell" rating in a report on Sunday, June 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, BioAge Labs currently has an average rating of "Sell".

BioAge Labs Price Performance

Shares of BIOA stock traded up $0.07 during mid-day trading on Wednesday, hitting $5.67. The company's stock had a trading volume of 188,560 shares, compared to its average volume of 236,990. BioAge Labs has a 52-week low of $2.88 and a 52-week high of $26.62. The company has a 50-day moving average of $4.85.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.04).

Institutional Investors Weigh In On BioAge Labs

A number of hedge funds have recently made changes to their positions in BIOA. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs in the second quarter worth about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company's stock worth $54,000 after buying an additional 5,976 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of BioAge Labs in the second quarter worth about $57,000. Intech Investment Management LLC purchased a new stake in shares of BioAge Labs in the second quarter worth about $60,000. Finally, Walleye Capital LLC purchased a new stake in shares of BioAge Labs in the second quarter worth about $64,000.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.